Medication info
DapaPlus Extended Release Tablet 10/500 Milligrams

DapaPlus Extended Release Tablet 10/500 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Pink biconvex oval extended-release film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP x 5]
Approval status
Active

MFDS item code 202300242 · Approved 2023.01.12 · Insurance code 648604490

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medication should provide the same dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may affect glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be evaluated every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used in adults with type 2 diabetes to assist dietary and exercise regimens in controlling blood sugar levels. In particular, it is important to carefully consider the cardiovascular event prevention effect of dapagliflozin in patients whose blood sugar is not adequately controlled and who have cardiovascular diseases or risk factors. Therefore, this medication is administered to contribute to diabetes management and the reduction of cardiovascular risk.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medication should provide the same dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may affect glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be evaluated every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Precautions

This medication is used for diabetes treatment and helps to control blood sugar. Before taking this medication, it is essential to verify that kidney function is normal. This medication should not be used in patients with significantly impaired kidney function, and caution is required in cases of reduced kidney function. This medication can rarely cause serious metabolic complications, such as lactic acidosis, so immediate consultation with a doctor is advised if symptoms like sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occur. Additionally, the risk of hypoglycemia may increase when used in conjunction with insulin or sulfonylureas, necessitating close monitoring of blood sugar changes and dosage adjustments as needed. This medication should not be administered to patients with acute conditions that may affect kidney function, such as dehydration, severe infections, or acute myocardial infarction. Before and after examinations using radiological iodine contrast agents, the administration of this medication should be temporarily suspended, and it should only be restarted once normal kidney function is confirmed. Pregnant or potentially pregnant women and nursing mothers should not take this medication and should discontinue it immediately if they are currently taking it. This medication contains lactose, so patients with certain genetic disorders should not take it. In elderly patients, kidney function decline is common, so kidney function should be regularly monitored and treatment should start at a minimum dose. While taking this medication, there is a risk of genital and urinary tract infections, so immediate treatment is required if symptoms of infection appear. Fluid volume reduction or symptoms of low blood pressure may occur, so it is essential for elderly patients or those taking diuretics to closely monitor blood pressure and fluid status. Vitamin B12 levels may decrease, so regular checks of vitamin B12 levels are recommended for long-term usage. Excessive alcohol intake may increase the risk of side effects from this medication, so alcohol should be avoided while taking it. This medication should be temporarily suspended for a certain period before and after surgery, and it should be resumed only after confirming that kidney function is normal post-surgery. During the administration of this medication, there may be failures in blood sugar control or abnormal symptoms, so regular blood sugar checks and consultations with a doctor are important. In the case of overdose, medical assistance should be sought immediately, and while the toxicity of this medication is generally mild, the risk may vary depending on kidney function. While taking this medication, dizziness and other symptoms may occur during driving or operating machinery, so caution is necessary. Finally, this medication should be stored out of reach of children and kept in its original container to prevent misuse or degradation of quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 82 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • atrial fibrillation
  • palpitations
  • insomnia
  • neurogenic hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius. This helps preserve the medication's efficacy and prevents degradation.

Appearance and packaging

Appearance

Pink biconvex oval extended-release film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.